Abattis Legal Proceedings Update

Vancouver, BC / ACCESSWIRE / November 7, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") ATTBF ATT, wishes to advise its shareholders that the U.S. Federal Court in Washington State has this morning declined to exercise federal jurisdiction over the Company's recently announced claims. As a preliminary jurisdictional matter, the court indicated that it did not believe it was an appropriate venue for legal proceedings relating to the state's Marijuana industry. While the Court stated that the Company had fought "valiantly" during the hearing in advocating for federal jurisdiction, it also made plain that, unlike other jurisdictions throughout the U.S. which had exercised jurisdiction, it was bound by a prior legal decision from the ninth circuit that narrowed the ability of the Court to exercise federal jurisdiction in a similar case. The Court took the extraordinary step, however, of warning the defendants that it's decision to decline exercising federal jurisdiction should not be considered "a win" as the Company was likely to refile it's allegations in Washington state court. As predicted in the ruling, the Company is in preparations to immediately refile its complaint and seek a temporary restraining order on an emergency basis in Washington state court. Unlike the federal system, Washington state courts generally align more closely with state law on claims based on disputes within the Marijuana industry. The Company will keep shareholders informed as information becomes available throughout the day.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Mike Withrow"
Michael Withrow, President & CEO

For further information, contact the Company's Investor Relations, Saf Dhillon at (604) 336.0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.